Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-28T23:30:21.524Z Has data issue: false hasContentIssue false

Metabolic syndrome in childhood

Published online by Cambridge University Press:  01 October 2007

Pablo Sanjurjo Crespo*
Affiliation:
Unidad de Metabolismo, Hospital de Cruces, Plaza de Cruces s/n, Cruces-Baracaldo (Vizcaya) 48903, Spain
Jose Angel Prieto Perera
Affiliation:
Unidad de Metabolismo, Hospital de Cruces, Plaza de Cruces s/n, Cruces-Baracaldo (Vizcaya) 48903, Spain
Fernando Andrade Lodeiro
Affiliation:
Unidad de Metabolismo, Hospital de Cruces, Plaza de Cruces s/n, Cruces-Baracaldo (Vizcaya) 48903, Spain
Luis Aldámiz-Echevarría Azuara
Affiliation:
Unidad de Metabolismo, Hospital de Cruces, Plaza de Cruces s/n, Cruces-Baracaldo (Vizcaya) 48903, Spain
*
Corresponding author: Email psanjurjo@hcru.osakidetza.net
Rights & Permissions [Opens in a new window]

Abstract

The so-called epidemic of childhood obesity has increased the interest in the metabolic syndrome (MS) due to the potential projection into adulthood. Prevalence of the MS in adolescents has been estimated to be 6.7% in young adults and 4.2% in adolescents. Figures rise up to 28.7% in overweight and obese adolescents.

The most widely accepted hypothesis links the syndrome to obesity. In the Bogalusa study, the best predictors were obesity and being in the upper quartile of basal insulin levels. Ethnic and genetic factors play a role in order to explain the syndrome in the non-obese population and the differences of interobesity.

The relationship between MS and type 2 diabetes and cardiovascular disease is well established in adults. This association can be suggested in children as well, although the syndrome in childhood urgently needs to be clearly defined. In this age group, it is also of great interest to identify diagnosis criteria of the so-called pre-MS.

Detection of the syndrome focuses mainly on obese and overweight young people. Other population groups such as newborns with low or high birth weight, infants with accelerated growth, or children of obese or with gestational diabetes mothers are at a higher risk of developing peripheral insulin resistance. The measurement of abdominal circumference can be a useful screening tool.

Physical exercise and restriction of saturated and trans fatty acids are basic for treatment. If reducing weight is necessary, a reduction of carbohydrate intake, especially for refined sugars, must be emphasised. Dietary fibre improves insulin sensitivity.

Type
Original Article
Copyright
Copyright © The Authors 2007

Although the metabolic syndrome (MS) was already identified 40 years ago, the agreed definition by World Health Organization (WHO) and National Cholesterol Education Program (NCEP) (Adult Treatment Panel III, ATP III) is very recent. Both definitions focus on dyslipaemia, obesity, hypertension and hyperglycaemia, but critical figures have been defined according to age, sex and sometimes the height of the individual (as described below).

The overall biochemical markers are hypertriglyceridaemia, low high-density lipoprotein-c (HDL-c), hyperglycaemia, hyperuricaemia, increased testosterone, plasminogen activator inhibitor (PAI) and fibrinogen. Associated clinical symptoms are obesity, hypertension, polycystic ovary, non-alcoholic greasy liver, acantosis nigricans, sleep apnoea and the clinical consequences are type 2 diabetes and cardiovascular disease (CVD).

Several epidemiologic studies of prevalence in adulthood have shown a physiopathologic relationship with type 2 diabetes and CVDReference Mokdad, Bowman, Ford, Vinicor, Marks and Koplan1, Reference Calle, Rodriguez, Walker-Thurmond and Thun2. The so-called epidemic of childhood obesity has increased the interest in this syndrome due to the potential projection into adulthood.

A new concept has been defined in relation to the MS, the syndrome of insulin resistance (IR), defined as a failure of the usual levels of insulin to provide glucose to the peripheral tissues and the liver, with failure in the inhibition of very low density lipoprotein synthesis. It would be a combination of peripheral insulin resistance (PIR) and hyperinsulinaemia. Neither all obese children suffer from PIR, nor those with adequate weight are sensitive to insulin. It is likely that the so-called prudent diet, which replaces saturated fat for an excess of carbohydrates, has favourable consequences to develop this syndrome. Type 2 diabetes would start when this syndrome exhausts the possibilities of enough pancreatic insulin secretion so as to compensate for the resistance and maintain the homoeostatic functions of the hormone.

Prevalence of metabolic syndrome in childhood

Diverse prevalence rates have been reported depending on the different definitions of the syndrome and analytical and somatometric cut-off values. Based on the definition by ATP III, prevalence has been estimated to be 6.7% in young adults and 4.2% in adolescents (males 6.1%).

Impact of obesity

Focused on the overweight and obese children and youth population, the figures rise up to 28.7% in the adolescent population (one has to bear in mind that according to NHANES III estimates, 15% of children between 6 and 19 years are overweight).

Ethnic impact

Studies carried out in the USA showed an increase of this syndrome in the Hispanic adolescent population in contrast with the Caucasian and the Afroamerican population. This increment would be associated basically to overweight, which has doubled in the last 10 years (23.4% in contrast with 12.7% in whites). Although the prevalence of obesity in Afroamerican adolescents is also high (23.6%), curiously the incidence of the MS is low. These data suggest that there is an ethnic factor independent of obesity.

Physiopathology of the metabolic syndrome

In spite of the consensus ATP III on the definition of the syndrome, its physiopathology is controversial. Generally, the most widely accepted hypothesis links the syndrome to obesity.

The Finish study about cardiovascular risk factors in childhood and youth explored predictors of the MS and established that a high basal insulin level was the best predictor. In the Bogalusa study, children between 8 and 17 years of age were followed up for a period of 11.6 years. In this study, the best predictors were obesity and also being in the upper quartile of basal insulin levels. However, the reason why some obese children develop this syndrome while others do not is still unknown. In this sense, Cruz and GoranReference Cruz and Goran3 have reported a study on sensitivity to insulin (measured by intravenous tolerance to glucose test) showing that after adjusting for the differences in adiposity (measured by X-ray absorptiometry), obese children with MS were 6.2% lower. It was the sensitivity to insulin and not the fat mass that correlated negatively with triglycerides and blood pressure, and positively with HDL-c. These findings suggest that it is PIR and not adiposity that is the physiopathological inductor of the syndrome. In spite of these findings, the physiopathological binomy obesity-PIR still prevails, especially when there is visceral fat accumulation.

In any case, ethnic and genetic factors play a role in order to explain the syndrome in the non-obese population and the differences of interobesity.

Genetic factors

The aetiology of PIR is multifactorial and the endocrine-metabolic factors of obtaining and expending energy are involved (energy homoeostasis); hypothalamus-hypophysis factors, such as melanocortine, all hormonal factors of adipose tissue (leptin, adiponectin, resistin, TNF-α, PPAR-α, PPAR-γ) and other factors such as ghrelin, serine-protease inhibitors and, of course, insulin are involved as well.

Among the studies on the gene directly involved in PIR, it is worth mentioning: (1) genes that codify the insulin receptor itself: IRS1

Strategies of screening and treatment of MS in childhood

Localisation of risk population

Taking into account the parameters and cut-off values established for the definition of the syndrome in the paediatric age, it can be deduced that the detection of the syndrome focuses mainly on obese and overweight young people. However, other population groups such as newborns with low or high birth weight, infants with accelerated growth, or children of obese or with gestational diabetes mothers are at a higher risk of developing PIRReference Boney, Verma, Tucker and Vohr14. The presence of clinical manifestations very much related with the MS, acantosis nigricans, polycystic ovary, non-alcoholic fatty liver obliges to searching for the syndrome.

The study of a family background (type 2 diabetes, obesity, hypertension, hypertriglyceridaemia) can be an important help in the localisation of a population at risk. The measurement of simple parameters such as abdominal circumference can be a useful tool in the population screening of these patients.

Treatment

Physical exercise is one of the pillars of treatment. It must be quotidian and intenseReference Kang, Gutin and Barbeau15, and adequate to the individual possibilities. It can be adapted to a programme of exercise (for instance walk or swim for 30 min every day). Weight-bearing exercise is also helpful.

Dietetic aspects of treatment imply the restriction of saturated and trans fatty acids. If reducing weight is necessary, it must be emphasized in the reduction of carbohydrate intake, especially for refined sugars.

Dietary fibre improves insulin sensitivity by different mechanisms. It has been reported that the consumption of whole-grain cereals improves insulin sensitivity in adolescentsReference Sinaiko, Jacobs and Steinberg16. Other foods such as soy protein (rich in isoflavones) and lineseed oil also improve insulin sensitivityReference Bhathena and Velasquez17.

Metformin and thiazolidinediones have been used in the pharmacological treatment of the severe forms of PIR, apparently with good resultsReference Freemark and Bursey18, Reference Ghazzi, Perez and Antonucci19.

For the management of dyslipaemia, fenofibrate and statines have been proposed. It is necessary to remember that the combination of both pharmaceuticals has caused occasionally serious episodes of rabdomiolisis.

Paediatric surgical treatment (intestinal bypass) is only recommended if there is risk of death due to complications of the syndrome such as sleep apnoea.

As a complementary treatment, other factors of atherogenic risk must be avoided, such as smoking or the consumption of alcohol.

Acknowledgements

Conflict of interest declaration: The authors had no conflicts of interest to report.

Authorship contributions: All the authors (P.S.C., J.A.P.P., F.A.L., L.A.-E.A.) declare that they participated sufficiently in the work to take full and public responsibility for its content.

References

1Mokdad, AH, Bowman, BA, Ford, ES, Vinicor, F, Marks, JS, Koplan, JP. The continuing epidemics of obesity and diabetes in the United States. Journal of the American Medical Association 2001; 286: 11951200.CrossRefGoogle ScholarPubMed
2Calle, EE, Rodriguez, C, Walker-Thurmond, K, Thun, MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New England Journal of Medicine 2003; 348: 16251638.CrossRefGoogle Scholar
3Cruz, ML, Goran, MI. The metabolic syndrome in children and adolescent. Current Diabetes Reports 2004; 4: 5362.CrossRefGoogle Scholar
4Borkman, MB, Storlien, LH, Pan, DA, Jenkins, AB, Chisholm, J, Campbell, LV. The relation between insulin sensivity and the fatty-acid composition of skeletal-muscle phospholipids. New England Journal of Medicine 1993; 328: 238244.CrossRefGoogle Scholar
5Baur, LA, O’Connor, J, Pan, DA, Kriketos, AD, Storlien, LH. The fatty acid composition of skeletal membrane phospholipid: its relationship with the type of feeding and plasma glucose levels in young children. Metabolism 1998; 47: 106112.CrossRefGoogle ScholarPubMed
6 National Institute of Health. The Third Report of the National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, MD: National Institute of Health, 2001.CrossRefGoogle Scholar
7Isomaa, B, Almgren, P, Tuomi, T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683689.CrossRefGoogle ScholarPubMed
8Berenson, GS, Srinivasan, SR, Bao, W. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults, The Bogalusa Hearth Study. New England Journal of Medicine 1998; 338: 16501656.CrossRefGoogle Scholar
9Fagot-Campagna, A, Saadine, JB, Flegal, KM, Beckles, GI. Diabetes, impaired fasting glucose, and elevated HB A1c in US adolescent: the third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24: 834837.CrossRefGoogle ScholarPubMed
10Sina, R, Fisch, G, Teague, B. Prevalence of impaired glucose tolerance among children and adolescent with marked obesity. New England Journal of Medicine 2002; 346: 802810.CrossRefGoogle Scholar
11Higgins, PB, Gower, BA, Hunter, GR, Goran, MI. Defining health-related obesity in prepuberal children. Obesity Research 2001; 9 (4): 223240.CrossRefGoogle Scholar
12Moreno, LA, Pineda, I, Rodriguez, G, Fleta, J, Sarria, A, Bueno, M. Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatrica 2002; 91: 13071312.CrossRefGoogle ScholarPubMed
13Ten, S, MacLaren, N. Insulin resistance syndrome in children. Journal of Clinical Endocrinology and Metabolism 2004; 89: 25262539.CrossRefGoogle ScholarPubMed
14Boney, CM, Verma, A, Tucker, R, Vohr, BR. Metabolic syndrome in chilhood: association with birth weight, maternal obesity and gestacional diabetes mellitus. Pediatrics 2005; 115: 290296.CrossRefGoogle Scholar
15Kang, HS, Gutin, B, Barbeau, P. Physical training improves insulin resistance syndrome markers in obese adolescents. Medicine and Science in Sports and Exercise 2002; 34: 19201927.CrossRefGoogle ScholarPubMed
16Sinaiko, AR, Jacobs, DR, Steinberg, J. Insulin resistance syndrome in childhood: associations of the euglicemic insulin clamp and fasting insulin with fatness and other risk factors. Journal of Pediatrics 2001; 139: 700707.CrossRefGoogle Scholar
17Bhathena, SJ, Velasquez, MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. American Journal of Clinical Nutrition 2002; 76: 11911201.CrossRefGoogle ScholarPubMed
18Freemark, M, Bursey, D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and family history of type 2 diabetes. Pediatrics 2001; 107: E55.CrossRefGoogle ScholarPubMed
19Ghazzi, MN, Perez, JE, Antonucci, TK. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglytazone Study Group. Diabetes 1997; 46: 433439.CrossRefGoogle ScholarPubMed